

Title (en)

METABOLITES FOR NK-I ANTAGONISTS FOR EMESIS

Title (de)

METABOLITEN FÜR NK-I-ANTAGONISTEN ZUR EMESIS

Title (fr)

METABOLITES POUR LES ANTAGONISTES NK-I CONTRE LE VOMISSEMENT

Publication

**EP 1863767 B1 20090311 (EN)**

Application

**EP 06707550 A 20060314**

Priority

- EP 2006002313 W 20060314
- EP 05102359 A 20050323
- EP 06707550 A 20060314

Abstract (en)

[origin: WO2006099968A1] The present invention relates to compounds of the general formula (I) wherein R is methyl; and R<sup>1</sup> is 4-methyl-4-oxy-piperazin-1-yl; or R is CH<sub>2</sub>OH and R<sup>1</sup> is 4-methyl-piperazin-1-yl or is 4-methyl-4-oxy-piperazin-1-yl; and to pharmaceutically acceptable acid addition salts thereof for the treatment of NK-I receptor related diseases.

IPC 8 full level

**C07D 213/75** (2006.01); **A61K 31/44** (2006.01); **A61P 25/22** (2006.01); **A61P 25/24** (2006.01)

CPC (source: EP KR US)

**A61K 31/4418** (2013.01 - KR); **A61K 31/444** (2013.01 - KR); **A61P 1/04** (2017.12 - EP); **A61P 1/08** (2017.12 - EP); **A61P 7/10** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 11/02** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/04** (2017.12 - EP); **A61P 25/06** (2017.12 - EP); **A61P 25/16** (2017.12 - EP); **A61P 25/18** (2017.12 - EP); **A61P 25/22** (2017.12 - EP); **A61P 25/24** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 25/36** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 37/08** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 213/75** (2013.01 - EP KR US); **C07D 401/04** (2013.01 - KR)

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

**WO 2006099968 A1 20060928**; AR 052949 A1 20070411; AT E425144 T1 20090315; AU 2006226665 A1 20060928; AU 2006226665 B2 20110127; BR PI0609699 A2 20100420; CA 2602445 A1 20060928; CA 2602445 C 20130820; CN 101146775 A 20080319; CN 101146775 B 20120718; DE 602006005624 D1 20090423; DK 1863767 T3 20090504; EP 1863767 A1 20071212; EP 1863767 B1 20090311; ES 2320590 T3 20090525; IL 185689 A0 20080106; IL 185689 A 20120531; JP 2008534454 A 20080828; JP 4768010 B2 20110907; KR 100903224 B1 20090617; KR 20070107146 A 20071106; MX 2007011489 A 20071011; NO 20074622 L 20071018; PL 1863767 T3 20090831; PT 1863767 E 20090327; RU 2007134901 A 20090427; RU 2404969 C2 20101127; TW 200700390 A 20070101; TW I316056 B 20091021; US 2006217393 A1 20060928; US 7211579 B2 20070501; ZA 200708029 B 20081126

DOCDB simple family (application)

**EP 2006002313 W 20060314**; AR P060101093 A 20060321; AT 06707550 T 20060314; AU 2006226665 A 20060314; BR PI0609699 A 20060314; CA 2602445 A 20060314; CN 200680009442 A 20060314; DE 602006005624 T 20060314; DK 06707550 T 20060314; EP 06707550 A 20060314; ES 06707550 T 20060314; IL 18568907 A 20070903; JP 2008502283 A 20060314; KR 20077021748 A 20070921; MX 2007011489 A 20060314; NO 20074622 A 20070912; PL 06707550 T 20060314; PT 06707550 T 20060314; RU 2007134901 A 20060314; TW 95109514 A 20060320; US 37604206 A 20060315; ZA 200708029 A 20070918